Yonsei Med J.  2011 Jan;52(1):196-198. 10.3349/ymj.2011.52.1.196.

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma

• Lee WS
• Kim DH
• Shin SH
• Woo SI
• Kwan J
• Park KS
• Park SD
• Yi HG
• Jeon SH

• KMID: 1106457
• DOI: http://doi.org/10.3349/ymj.2011.52.1.196

Abstract

Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients' symptoms disappeared.

Keyword

Bortezomib; multiple myeloma; adverse effect; atrioventricular block

MeSH Terms

Atrioventricular Block/*chemically induced
Boronic Acids/*adverse effects/*therapeutic use
Female
Humans
Middle Aged
Multiple Myeloma/*drug therapy
Pyrazines/*adverse effects/*therapeutic use

Figure

• 

  Fig. 1 Chest X-ray at admission. The chest X-ray is normal with a slight cardiomegaly.

• 

  Fig. 2 (A) A 12-lead electrocardiogram of the patient before using bortezomib. No specific ST or T abnormalities, with normal sinus rhythm. (B) A 12-lead electrocardiogram of the patient at admission. More P waves than the QRS complexes and dissociation with P waves and QRS complexes, which stands for complete atrioventricular block.

• 

  Fig. 3 (A) Chest X-ray after pacemaker insertion. The pacemaker lead is shown at the apex of right ventricle in the X-ray (arrow), which indicates successful pacemaker insertion. (B) A 12-lead electrocardiogram after insertion of pacemaker. The electrocardiogram shows successful pacing of the pacemaker.

Reference

1. Dasanu CA. Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract. 2010. 04. 20. [Epub ahead of print].

2. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs. 2004. 8:473–480.

3. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007. 204:317–325.

4. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004. 10:6111–6118.

5. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005. 104:2141–2148.

6. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009. 114:1489–1497.